ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "MEI Pharma, Inc." (MEIP) Report Updated: Apr 25, 2016 | Print This Page

Get more stock ratings by Louis Navellier

"MEI Pharma, Inc." (MEIP)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors:

Stock Analysis

Rating: Monthly View

A
B
C
D
F
May June July August September October November December January February March April

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"MEI Pharma, Inc."© quotemedia

Company Profile

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company’s clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as acute myeloid leukemia and myelodysplastic syndrome. Its clinical development pipeline also includes ME-344, an isoflavone-derived mitochondrial inhibitor drug candidate that is in Phase I clinical trial to treat refractory solid tumors; and PWT143, an oral inhibitor of phosphatidylinositide 3-kinase, which is in pre-clinical stage for the treatment of cancer. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California.